文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性生理学与慢性健康状况评分Ⅱ在慢性阻塞性肺疾病急性加重患者无创通气时机选择中的应用

[Application of acute physiology and chronic health evaluation II score in the timing of noninvasive ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论对AECOPD患者,APACHEⅡ评分>10分时启动无创通气、≤10分时撤机,并据评分分层护理,可改善肺功能并降低插管率、VAP发生率及ICU死亡率。

该研究将106例AECOPD患者随机分为观察组与对照组各53例。对照组按《机械通气(第二版)》标准选择无创通气时机、按《机械通气临床实践》撤机并接受ICU常规护理;观察组在APACHEⅡ评分>10分时启动无创通气、≤10分时撤机,并按评分<10、10-14、15-19、≥20分分别给予三级、二级、一级护理和重症护理。无创通气3天后观察组FEV1、FVC及FEV1/FVC均高于对照组,机械通气时间及ICU住院时间缩短,插管率、VAP发生率及ICU死亡率均低于对照组,护理满意度高于对照组。作者认为APACHEⅡ评分可用于指导AECOPD患者无创通气时机与护理措施的选择。

要点

  • 观察组在APACHEⅡ评分>10分时启动无创通气、≤10分时撤机,对照组按《机械通气(第二版)》标准选择时机、按《机械通气临床实践》撤机。
  • 无创通气3天后FEV1观察组3.02±0.22 L vs 对照组2.54±0.19 L,FVC 3.01±0.32 L vs 2.13±0.28 L,FEV1/FVC 0.89±0.08 vs 0.79±0.08,均P<0.05。
  • 观察组机械通气时间4.32±0.73天 vs 对照组8.42±1.94天,ICU住院时间32.23±10.22小时 vs 38.52±9.85小时,均P<0.01。
  • 观察组插管率1.9%(1/53) vs 对照组13.2%(7/53),VAP发生率1.9%(1/53) vs 15.1%(8/53),ICU死亡率1.9%(1/53) vs 13.2%(7/53),均P<0.05。
  • 观察组护理满意度96.2%(51/53) vs 对照组75.5%(40/53),P<0.01。

适用人群与场景

  • 2018年1月至2019年10月海口市人民医院收治的AECOPD患者106例,随机数字表法分为观察组与对照组各53例。

诊断标准与关键阈值

  • 观察组以APACHEⅡ评分>10分作为启动无创通气的时机,以APACHEⅡ评分≤10分作为撤机时机。
  • 观察组按APACHEⅡ评分<10分、10-14分、15-19分、≥20分分别给予三级护理、二级护理、一级护理、重症护理。

处置流程与药物剂量

  • 对照组按《机械通气(第二版)》标准选择无创通气治疗时机,按《机械通气临床实践》撤机,并接受ICU常规护理,包括创造舒适室内环境、合理饮食、病情监测、心理护理及并发症护理。
  • 观察组在对照组基础上,于APACHEⅡ评分>10分时给予无创通气,于APACHEⅡ评分≤10分时撤机。
  • 观察组按APACHEⅡ评分<10分、10-14分、15-19分、≥20分分别实施三级护理、二级护理、一级护理、重症护理。

研究设计与关键结果

  • 研究类型为随机对照研究,样本量106例(观察组53例、对照组53例),人群为AECOPD患者;干预为按APACHEⅡ评分>10分启动无创通气、≤10分撤机并按评分分层护理,对照为按《机械通气(第二版)》标准选择时机、按《机械通气临床实践》撤机并接受ICU常规护理。
  • 无创通气3天后肺功能较治疗前均升高,观察组FEV1(L)3.02±0.22 vs 对照组2.54±0.19,FVC(L)3.01±0.32 vs 2.13±0.28,FEV1/FVC比值0.89±0.08 vs 0.79±0.08,均P<0.05。
  • 观察组机械通气时间(天)4.32±0.73 vs 对照组8.42±1.94,ICU住院时间(小时)32.23±10.22 vs 38.52±9.85,均P<0.01。
  • 观察组插管率1.9%(1/53) vs 对照组13.2%(7/53),VAP发生率1.9%(1/53) vs 15.1%(8/53),ICU死亡率1.9%(1/53) vs 13.2%(7/53),均P<0.05。
  • 观察组护理满意度96.2%(51/53) vs 对照组75.5%(40/53),P<0.01。
  • 两组性别、年龄等一般资料比较无显著差异。

证据类型、等级与局限

  • 证据类型:随机对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为APACHEⅡ评分可用于指导AECOPD患者无创通气治疗时机及护理干预措施的选择,可改善患者肺功能、提高治疗效果、减少并发症发生率并提高护理满意度。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the application of acute physiology and chronic health evaluation II (APACHE II) score in the timing and nursing of noninvasive ventilation for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

METHODS: 106 AECOPD patients admitted to Haikou People's Hospital from January 2018 to October 2019 were selected as the study objects. According to the method of random number table, the patients were divided into observation group and control group, with 53 patients in each group. The control group selected the timing of noninvasive ventilation treatment according to the standards of Mechanical ventilation (second edition), weaned according to Clinical practice of mechanical ventilation, and received routine nursing in intensive care unit (ICU), including creating comfortable indoor environment, reasonable diet, condition monitoring, psychological nursing and complications nursing. On the basis of the control group, the patients in the observation group were given noninvasive ventilation when APACHE II score was more than 10, and were weaned when APACHE II score was less than or equal to 10. According to APACHE II score < 10, 10-14, 15-19 and ≥ 20, the patients were given level-3 care, level-2 care, level-1 care and intensive care. The pulmonary function before and 3 days after the noninvasive ventilation treatment was monitored, and the duration of mechanical ventilation, the length of ICU stay, endotracheal intubation rate, incidence of complication [ventilator associated pneumonia (VAP)] and ICU mortality were recorded. The self-designed questionnaire of nursing satisfaction was used to evaluate the patients' nursing satisfaction.

RESULTS: There was no significant difference in general data such as gender or age between the two groups. After 3 days of noninvasive ventilation, the forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio of the two groups were increased significantly as compared with those before treatment, especially in the observation group, with statistical significances as compared with the control group [FEV1 (L): 3.02±0.22 vs. 2.54±0.19, FVC (L): 3.01±0.32 vs. 2.13±0.28, FEV1/FVC ratio: 0.89±0.08 vs. 0.79±0.08, all P < 0.05]. Compared with the control group, the duration of mechanical ventilation and length of ICU stay in the observation group were significantly shortened [duration of mechanical ventilation (days): 4.32±0.73 vs. 8.42±1.94, length of ICU stay (hours): 32.23±10.22 vs. 38.52±9.85, both P < 0.01]. The intubation rate, incidence of VAP and ICU mortality in the observation group were significantly lower than those in the control group [intubation rate: 1.9% (1/53) vs. 13.2% (7/53), incidence of VAP: 1.9% (1/53) vs. 15.1% (8/53), ICU mortality: 1.9% (1/53) vs. 13.2% (7/53), all P < 0.05]. The nursing satisfaction of patients in the observation group was significantly higher than that in the control group [96.2% (51/53) vs. 75.5% (40/53), P < 0.01].

CONCLUSIONS: APACHE II score can be used to guide the choice of noninvasive ventilation treatment opportunity and nursing intervention measures for AECOPD patients. It can significantly improve the pulmonary function of patients, improve the treatment effect, reduce the incidence of complications, and improve the satisfaction of patients with nursing, which is effective in clinical application.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Chen J, Wang W, Qiu W, et al. [Application of acute physiology and chronic health evaluation II score in the timing of noninvasive ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32576351. doi:10.3760/cma.j.cn121430-20200106-00159

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。